- Home
- SKYE vs MGTX Comparison
SKYE vs MGTX Comparison
Compare SKYE & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- MGTX
- Stock Information
- Founded
- SKYE 2012
- MGTX 2015
- Country
- SKYE United States
- MGTX United States
- Employees
- SKYE N/A
- MGTX N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKYE Health Care
- MGTX Health Care
- Exchange
- SKYE Nasdaq
- MGTX Nasdaq
- Market Cap
- SKYE 73.4M
- MGTX 520.8M
- IPO Year
- SKYE N/A
- MGTX N/A
- Fundamental
- Price
- SKYE $3.74
- MGTX $6.48
- Analyst Decision
- SKYE Buy
- MGTX Strong Buy
- Analyst Count
- SKYE 6
- MGTX 2
- Target Price
- SKYE $16.60
- MGTX $24.00
- AVG Volume (30 Days)
- SKYE 2.0M
- MGTX 441.5K
- Earning Date
- SKYE 08-08-2025
- MGTX 08-11-2025
- Dividend Yield
- SKYE N/A
- MGTX N/A
- EPS Growth
- SKYE N/A
- MGTX N/A
- EPS
- SKYE N/A
- MGTX N/A
- Revenue
- SKYE N/A
- MGTX $34,508,000.00
- Revenue This Year
- SKYE N/A
- MGTX $365.04
- Revenue Next Year
- SKYE N/A
- MGTX $73.18
- P/E Ratio
- SKYE N/A
- MGTX N/A
- Revenue Growth
- SKYE N/A
- MGTX 203.23
- 52 Week Low
- SKYE $1.14
- MGTX $3.85
- 52 Week High
- SKYE $8.26
- MGTX $8.75
- Technical
- Relative Strength Index (RSI)
- SKYE 66.59
- MGTX 56.28
- Support Level
- SKYE $2.12
- MGTX $6.07
- Resistance Level
- SKYE $5.75
- MGTX $6.80
- Average True Range (ATR)
- SKYE 0.55
- MGTX 0.36
- MACD
- SKYE 0.17
- MGTX 0.00
- Stochastic Oscillator
- SKYE 45.82
- MGTX 41.84
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.